Brentuximab vedotin, an ADC targeting CD30, is FDA-approved in combination with CHP as front-line treatment for patients with CD30 expressing PTCL. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.